Your session is about to expire
← Back to Search
evinacumab for High Triglycerides
Study Summary
This trial is testing whether a drug called evinacumab can prevent recurrent episodes of acute pancreatitis in patients with elevated triglycerides.
- High Triglycerides
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2020 Phase 3 trial • 65 Patients • NCT03399786Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Is the age restriction of this medical trial limited to individuals under 25 years old?
"Prospective participants of this medical trial must be over 18 years old and under 80 to qualify."
Is this trial the inaugural instance of its category?
"Research into evinacumab began in 2018, when a Regeneron-sponsored trial was conducted on 116 patients. Following this initial study and its Phase 3 approval, there are now 3 active trials being held across 14 nations and 57 cities."
What potential risks come with utilizing evinacumab?
"On our safety assessment scale, evinacumab was rated a 2 as there is clinical evidence supporting its safety but not efficacy."
Is this scientific experiment still recruiting participants?
"Data hosted on clinicaltrials.gov shows that this medical study is no longer accepting participants, having been initially posted on July 12th 2021 and last updated September 30th 2022. However, 102 other trials are open for recruitment at the current time."
Could I qualify to join this clinical research study?
"This clinical trial is looking to enrol 21 adults aged 18-80 who have been diagnosed with hypertriglyceridemia. Eligible participants must meet the following criteria: lack of FCS due to lipoprotein lipase (LPL) loss of function mutations, documented history of one HTG-associated acute pancreatitis episode within 24 months prior to screening, fasting serum triglyceride levels higher than 880mg/dL or 500 mg/dL during the same period described in the protocol, current and stable lipid-lowering therapy for at least 8 weeks before enrollment that they are willing to maintain throughout the study duration, body mass index"
Are there any medical centers running this investigation in the city?
"A plethora of medical facilities such as Saint Louis University in Saint Louis, Medical College of Wisconsin in Milwaukee, and NorthShore Medical Group in Evanston are currently participating this trial. A total of 39 sites have been identified for enrolment."
Could you elaborate on the past research conducted with evinacumab?
"Currently, 3 studies are underway to study evinacumab's efficacy. Of these investigations, 2 have reached Phase 3 of the process. Clinics in 92 locations across Kharkiv and California are running trials for this medication."
What is the scope of this research in regard to patient numbers?
"This clinical trial is not currently enrolling participants; it was first published on July 12th, 2021 and its most recent entry is from September 30th 2022. If you are searching for other trials targeting hypertriglyceridemia, there are 99 studies in progress while evinacumab can be found in 3 active trials."
Share this study with friends
Copy Link
Messenger